You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

766 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative, Palliative
Nov 2017
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    osimertinib - For the treatment of locally advanced (not amenable to curative therapies) or metastatic non-small cell lung cancer (NSCLC) according to clinical criteria
Dec 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Jun 2019
Statistical Reports
*/ For the most recent data, refer to the Ontario Cancer Screening Performance Report 2023.
May 2017
Document
Document
Document

Pages